THE CENTRAL CONCERN
Rapid weight loss and nutritional vulnerability
Potent appetite suppression, reduced dietary intake, gastrointestinal intolerance and rapid weight reduction may create nutritional vulnerability in some individuals. Panacea Bio Chem is investigating whether integrating thiamine into a once-weekly retatrutide formulation could provide a more coherent pharmaceutical research architecture. This is the retatrutide-associated nutritional vulnerability question — and it is the scientific reason the Rethiamine formulation exists.
What the story is not: it is not an assertion that retatrutide has been shown to deplete vitamin B1. Direct retatrutide-induced biochemical depletion of thiamine has not been established. The concern is indirect — intake, tolerance and rate of loss — and it is shared by the wider incretin class, not unique to one molecule.
The 2026 tri-society consensus
The EASO, EFAD and ECPO consensus statement on incretin-based therapies ↗ is the first tri-society consensus on nutrition during incretin therapy: protein targets, resistance exercise, and explicit micronutrient-risk monitoring during rapid weight loss. What it supports: nutritional monitoring is a mainstream, society-level component of incretin treatment research — not a fringe concern. What it does not prove: that any specific micronutrient supplementation strategy changes outcomes; the statement frames monitoring and targets, not formulation answers.
A parallel “high-quality weight loss” framework ↗ argues for preferential fat reduction with preserved muscle, function, dietary adequacy and bone — and notes that total weight alone cannot distinguish fat, lean tissue, water and bone. That is the beyond-the-scale thesis this site is built on.
The pillars of nutritional resilience
The levers the literature actually names are structural, not supplemental: adequate protein (reviews of at-risk groups cite 1.2–1.6 g/kg/day); micronutrient intake; resistance exercise; hydration; clinical monitoring; management of gastrointestinal symptoms; and the rate of weight reduction itself. The Lundgren trial ↗ showed exercise plus liraglutide outperforming either alone for maintenance — evidence that structured exercise is a necessary adjunct to incretin therapy, not an optional extra.
Nothing on this site implies that the proposed 20 mg thiamine component replaces a complete nutrition programme. It does not. The formulation question — whether thiamine integration may contribute to a more nutritionally considered retatrutide architecture — sits downstream of these pillars, not in place of them. Monitoring practice is detailed under nutrition monitoring during major weight reduction, and the muscle-specific frame under retatrutide and muscle loss.